N²-(4-fluorophenyl)pyridine-2,3-diamine | 41010-70-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N²-(4-fluorophenyl)pyridine-2,3-diamine
• 英文别名: N2-(4-fluorophenyl)pyridine-2,3-diamine；3-amino-2-(4-fluorobenzeneamino)pyridine；2-N-(4-fluorophenyl)pyridine-2,3-diamine
• CAS: 41010-70-2
• 化学式: C₁₁H₁₀FN₃
• mdl: MFCD11201955
• 分子量: 203.219
• InChiKey: KANSXBGVFUJMTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N²-(4-fluorophenyl)pyridine-2,3-diamine 在 盐酸 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 为溶剂， 以88%的产率得到3-(4-fluorophenyl)-3H-[1,2,3]triazolo[4,5-b]pyridine
  参考文献：
  名称：

  1,2,3-三唑与吡啶/嘧啶融合作为抗菌剂的新模板：区域选择性合成和强力N-杂芳烃的鉴定

  摘要：

  探索与吡啶/嘧啶稠合的1,2,3-三唑环作为鉴定潜在抗菌剂的新模板。这些预先设计的N-杂芳烃的区域选择性合成是通过探索将Buchwald策略（即C–N键形成/还原/重氮化/环化顺序）应用于N-杂芳烃体系而实现的。它们中的两个显示出有希望的抗菌作用（与链霉素相当），另外几个显示出有效的抗真菌作用（与mancozeb相当）。

  DOI：

  10.1016/j.bmcl.2018.09.021
• 作为产物：
  描述：

  2-氯-3-硝基吡啶 在 tin(II) chloride dihdyrate 作用下， 以 甲醇 、 乙二醇 为溶剂， 反应 8.0h， 生成 N²-(4-fluorophenyl)pyridine-2,3-diamine
  参考文献：
  名称：

  合理设计和合成2-苯胺基吡啶基-苯并噻唑席夫碱作为抗有丝分裂剂。

  摘要：

  根据我们以前的结果和文献的先验，通过对一些选定的分子进行分子建模实验，合理设计了一系列2-苯胺基吡啶基-苯并噻唑席夫碱。对接分子的结合能优于E7010，苯并噻唑部分带有三甲氧基的席夫碱为4y最佳。然后通过便利的合成途径合成一系列设计的分子，并评估其抗癌潜力。大多数化合物对受试细胞系均显示出显着的生长抑制作用，并且化合物4y表现出良好的抗增殖活性，尤其是针对DU145细胞系的GI50值为3.8µM。与对接结果一致，4y通过有效结合到秋水仙碱域中来抑制微管蛋白聚合，从而破坏微管动力学，从而产生了细胞毒性，与E7010相当。通过分子对接研究了4y与微管蛋白秋水仙碱结合位点的详细结合方式。此外，正如线粒体膜电位，caspase-3和膜联蛋白V-FITC分析等生物学研究所证明的，4y诱导了细胞凋亡。

  DOI：

  10.1016/j.bmcl.2017.03.089

文献信息

• Rational design and synthesis of 2-anilinopyridinyl-benzothiazole Schiff bases as antimitotic agents
  作者：Thokhir B. Shaik、S.M. Ali Hussaini、V. Lakshma Nayak、M. Lakshmi Sucharitha、M. Shaheer Malik、Ahmed Kamal

  DOI：10.1016/j.bmcl.2017.03.089

  日期：2017.6

  base with trimethoxy group on benzothiazole moiety, 4y was the best. This was followed by the synthesis of a series of the designed molecules by a convenient synthetic route and evaluation of their anticancer potential. Most of the compounds have shown significant growth inhibition against the tested cell lines and the compound 4y exhibited good antiproliferative activity with a GI50 value of 3.8µM specifically

  根据我们以前的结果和文献的先验，通过对一些选定的分子进行分子建模实验，合理设计了一系列2-苯胺基吡啶基-苯并噻唑席夫碱。对接分子的结合能优于E7010，苯并噻唑部分带有三甲氧基的席夫碱为4y最佳。然后通过便利的合成途径合成一系列设计的分子，并评估其抗癌潜力。大多数化合物对受试细胞系均显示出显着的生长抑制作用，并且化合物4y表现出良好的抗增殖活性，尤其是针对DU145细胞系的GI50值为3.8µM。与对接结果一致，4y通过有效结合到秋水仙碱域中来抑制微管蛋白聚合，从而破坏微管动力学，从而产生了细胞毒性，与E7010相当。通过分子对接研究了4y与微管蛋白秋水仙碱结合位点的详细结合方式。此外，正如线粒体膜电位，caspase-3和膜联蛋白V-FITC分析等生物学研究所证明的，4y诱导了细胞凋亡。
• 3,4-Dihydro-3-oxopyrido[2,3-b]-pyrazines, compositions and use thereof
  申请人：Fisons Limited

  公开号：US04296114A1

  公开（公告）日：1981-10-20

  There are described compounds of formula I, ##STR1## in which R.sub.1 is phenyl substituted by halogen, alkoxy, alkyl, carboxy-alkyl, --NR.sub.4 R.sub.5, carboxy or alkoxy carbonyl, R.sub.3 is hydrogen, alkyl, mono- or di-carboxy alkyl, halo, alkoxy, phenyl, halo-phenyl, hydroxy, phenoxy, thiol, thioalkoxy, thiophenoxy, --NR.sub.4 R.sub.5, cyano, --COOH, carboxyureido, --CF.sub.3, --COR.sub.6, hydroxyalkyl, aminoalkyl, or alkoxy substituted by NR.sub.4 R.sub.5, ring A is a benzene or a pyridine ring which optionally carries up to 4 substituents R.sub.3, which may be the same or different, R.sub.4 and R.sub.5, which may be the same or different, each represent hydrogen, phenyl, halophenyl or alkyl, the alkyl optionally being substituted by alkoxy or by a mono- or di-alkyl or unsubstituted amino group; or R.sub.4 and R.sub.5, together with the nitrogen atom to which they are attached, form a piperidine, morpholine or an optionally alkyl substituted piperazine ring, and R.sub.6 is hydrogen or alkyl, provided that (i) when R.sub.1 is phenyl substituted by chlorine or bromine, ring A is not a benzene ring substituted by chlorine or bromine, or (ii) when R.sub.1 is phenyl substituted by methoxy R.sub.3 is not phenyl, and pharmaceutically acceptable salts, esters and amides thereof. There are also described methods for making the compounds and pharmaceutical, e.g. anti-inflammatory, compositions containing the compounds.

  描述了式I的化合物，其中R.sub.1是被卤素、烷氧基、烷基、羧基烷基、--NR.sub.4 R.sub.5、羧基或烷氧基羰基取代的苯基，R.sub.3是氢、烷基、单或双羧基烷基、卤素、烷氧基、苯基、卤代苯基、羟基、苯氧基、硫醇、硫代烷氧基、硫代苯氧基、--NR.sub.4 R.sub.5、氰基、--COOH、羧基脲基、--CF.sub.3、--COR.sub.6、羟基烷基、氨基烷基，或被NR.sub.4 R.sub.5取代的烷氧基，环A是苯环或吡啶环，可选地带有多达4个取代基R.sub.3，这些取代基可以相同也可以不同，R.sub.4和R.sub.5，可以相同也可以不同，每个代表氢、苯基、卤代苯基或烷基，其中烷基可选地被烷氧基、单烷基或双烷基或未取代氨基取代；或R.sub.4和R.sub.5，连同它们连接的氮原子，形成哌啶、吗啡或可选地烷基取代的哌嗪环，R.sub.6是氢或烷基，但是当R.sub.1是被氯或溴取代的苯基时，环A不是被氯或溴取代的苯环，或者当R.sub.1是被甲氧基取代的苯基时，R.sub.3不是苯基，以及药学上可接受的盐、酯和酰胺。还描述了制备这些化合物的方法和含有这些化合物的药物，例如抗炎药物。
• Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
  申请人：FISONS plc

  公开号：EP0008864A1

  公开（公告）日：1980-03-19

  There are described compounds of formula I, in which R1 is phenyl substituted by halogen, alkoxy, alkyl, carboxy-alkyl, -NR4R5, carboxy or alkoxy carbonyl, R3 is hydrogen, alkyl, mono- or di-carboxy alkyl, halo, alkoxy, phenyl, halo-phenyl, hydroxy, phenoxy, thiol, thioalkoxy, thiophenoxy, -NR4Rs, cyano, -COOH, carboxyureido, -CF3, -CORe, hydroxyalkyl, aminoalkyl, or alkoxy substituted by NR4R5, ring A is a benzene or a pyridine ring which optionally carries up to 4 substituents R3, which may be the same or different, R4 and Rs, which may be the same or different, each represent hydrogen, phenyl, halophenyl or alkyl, the alkyl optionally being substituted by alkoxy or by a mono- or di- alkyl or unsubstituted amino group; or R4 and Rs, together with the nitrogen atom to which they are attached, form a piperidine, morpholine or an optionally alkyl substitued piperazine ring, and R6 is hydrogen or alkyl, provided that (i) when R, is phenyl substituted by chlorine or bromine, ring A is not a benzene ring substituted by chlorine or bromine, or (ii) when R, is phenyl substituted by methoxy R3 is not phenyl, and pharmaceutically acceptable salts, esters and amides thereof. There are also described methods for making the compounds and pharmaceutical, e.g. anti-inflammatory, compositions containing the compounds.

  所述化合物为式 I、 其中 R1 是被卤素、烷氧基、烷基、羧基、-NR4R5、羧基或烷氧基羰基取代的苯基、 R3 是氢、烷基、一羧基或二羧基烷基、卤素、烷氧基、苯基、卤代苯基、羟基、苯氧基、硫醇、硫代烷氧基、噻吩氧基、-NR4Rs、氰基、-COOH、羧基脲基、-CF3、-CORe、羟基烷基、氨基烷基或被 NR4R5 取代的烷氧基、 环 A 是苯环或吡啶环，可选择带有最多 4 个取代基 R3，它们可以相同或不同、 R4和Rs（可以相同或不同）各自代表氢、苯基、卤代苯基或烷基，烷基可选择被烷氧基或单烷基或二烷基或未取代的氨基取代；或R4和Rs与它们所连接的氮原子一起形成哌啶、吗啉或可选择被烷基取代的哌嗪环，以及 R6 为氢或烷基、 但 (i) 当 R 为被氯或溴取代的苯基时，环 A 不是被氯或溴取代的苯环，或 (ii) 当 R 为被甲氧基取代的苯基时，R3 不是苯基、 及其药学上可接受的盐、酯和酰胺。 此外，还介绍了制造这些化合物的方法以及含有这些化合物的药物组合物，例如消炎组合物。
• Synthesis of 2-anilinopyridine dimers as microtubule targeting and apoptosis inducing agents
  作者：Ahmed Kamal、S.M. Ali Hussaini、V. Lakshma Nayak、M. Shaheer Malik、M. Lakshmi Sucharitha、Thokhir Basha Shaik、Md. Ashraf、Chandrakant Bagul

  DOI：10.1016/j.bmc.2014.11.001

  日期：2014.12

  A series of 2-anilinopyridine dimers have been synthesized and evaluated for their anticancer potential. Most of the compounds have showed significant growth inhibition of the cell lines tested and compound 4d was most effective amongst the series displaying a GI(50) of 0.99 mu M specifically against the prostate cancer cell line (DU145). Studies to understand the mechanism of action of 4d indicates that it disrupts microtubule dynamics by inhibiting tubulin polymerization thereby arresting the cell cycle in G2/M phase. Competitive colchicine binding assay suggests that 4d binds into colchicine binding site of the tubulin. Further from some detailed biological studies like mitochondrial membrane potential, caspase-3 assay, DNA fragmentation analysis and Annexin V-FITC assay it is evident that 4d induces apoptosis. Molecular modeling studies provide an insight into the binding modes of 4d with colchicine binding site of tubulin and the data obtained correlates with the antiproliferative activity. (C) 2014 Elsevier Ltd. All rights reserved.
• CLARK R. L.; PESSOLANO A. A.; SHEN T.-Y.; JACOBUS D. P.; JONES H.; LOTTI +, J. MED. CHEM., 1978, 21, NO 9, 965-978
  作者：CLARK R. L.、 PESSOLANO A. A.、 SHEN T.-Y.、 JACOBUS D. P.、 JONES H.、 LOTTI +

  DOI：——

  日期：——